-The Hindu Health activists remind the Prime Minister of his last year's promise of free medication which will fulfil people's right to essential medicines Last year during his Independence Day speech from the ramparts of the Red Fort, Prime Minister Manmohan Singh had announced free distribution of medicines through government hospitals and health centres. One year down the line, however, the promise is far from being fulfilled and the declaration has made...
More »SEARCH RESULT
Total Matching Records found : 281
Branded medicines cost 15 times more than generic ones
-The Times of India NEW DELHI: Branded medicines cost 2-15 times more than non-branded generic medicines sold at Jan Aushadhi stores. For example, a 10-tablet strip of Diclofenac SR (100mg), a popular pain killer, costs Rs 51.91 whereas the same generic medicine costs only Rs 3.35 at Jan Aushadhi stores. An 100 ml bottle of cough syrup manufactured and marketed by drug companies costs Rs 33 while those sold at Jan Aushadhi...
More »Drug price policy under SC glare
-The Telegraph New Delhi: The Supreme Court today ticked off the government for "dilly dallying" on an affordable drug pricing policy, following a petition that said the delay was aimed at pushing through suggestions of the powerful manufacturers' lobby. A bench of Justices G.S. Singhvi and Gopala Gowda asked the Centre to respond within six weeks. The All India Drug Action Network (AIDAN) had filed the application saying the government was delaying a...
More »Price control, IP Act & regulatory framework: Revisiting some imp issues about Indian pharma-Ramesh Adige
-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »SMS, RTI potent tools of drug companies fighting patent battle -Soma Das
-The Economic Times NEW DELHI: As patent wars heat up in the pharma space, mobile phone messages and Right to Information filings have emerged as potent weapons in the hands of multinationals keen to delay competition from low-cost generic versions of their patented products in India. Innovator drugmakers, who used to strike with patent suits after generic drugmakers released their versions in the market, have started gleaning information from text messages sent...
More »
